Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article].
AffiliationMédecins Sans Frontières, Khayelitsha, Cape Town, South Africa; Monash University, Melbourne, Victoria, Australia; ‡ Médecins Sans Frontières, London, UK; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa
MetadataShow full item record
AbstractBACKGROUND: Current treatment for drug-resistant tuberculosis (DR-TB) is inadequate, and outcomes are significantly poorer than for drug-susceptible TB, particularly for patients previously treated with second-line drugs, treatment failures or extensively drug-resistant (XDR-) TB patients (complicated DR-TB). Linezolid is not recommended for routine DR-TB treatment due to the lack of efficacy data, but is suggested for patients where adequate second-line regimens are difficult to design.OBJECTIVE: To conduct a systematic review and metaanalysis to assess existing evidence of efficacy and safety of linezolid for DR-TB treatment.METHODS: We searched PubMed, Embase and abstracts from World Conferences of The Union for studies published through February 2011. We included all studies in which linezolid was given systematically to DR-TB patients and where treatment outcomes were reported.RESULTS: A total of 11 studies were included in our review, representing 148 patients. The pooled proportion for treatment success was 67.99% (95%CI 58.00-78.99, τ2 129.42). There were no significant differences in success comparing daily linezolid dose (≤600 vs. >600 mg) and mean linezolid duration (≤7 vs. >7 months). The pooled estimate for the frequency of any adverse events was 61.48% (95%CI 40.15-82.80), with 36.23% (95%CI 20.67-51.79) discontinuing linezolid due to adverse events.CONCLUSION: Treatment success with linezolid was equal to or better than that commonly achieved for uncomplicated DR-TB, and better than previous reports for previously treated patients and those with XDR-TB. While data are limited, linezolid appears be a useful drug, albeit associated with significant adverse events, and should be considered in the treatment of complicated DR-TB.
- Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
- Authors: Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS
- Issue date: 2012 Dec
- Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations.
- Authors: Garcia-Prats AJ, Rose PC, Hesseling AC, Schaaf HS
- Issue date: 2014 Mar
- Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
- Authors: Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, Shim TS
- Issue date: 2009 Aug
- Linezolid in the treatment of MDR-TB: a retrospective clinical study.
- Authors: Xu HB, Jiang RH, Li L, Xiao HP
- Issue date: 2012
- Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
- Authors: Alffenaar JW, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AM, van Soolingen D, Kosterink JG, Uges DR, van der Werf TS
- Issue date: 2010 Aug